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Abstract: First characterized by Stroebe, the gliosarcomas are highly malignant and rare 
primary tumor of the brain composed of neoplastic glial cells in association with spindle 
cell sarcomatous elements (biphasic tissue patterns). In spite of being recognized as two 
different pathologies studies have not shown any significant differences between 
gliosarcoma and glioblastoma with regard to age, sex, size, clinical presentation, and 
median survival. In summary, gliosarcoma is an aggressive tumor with a propensity to 
recur and re-grow with poor outcome. Future studies are needed to understand the true 
pathology of these biphasic tumors. 
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Introduction 
First characterized by Stroebe, (1) the 
gliosarcomas are highly malignant and rare 
primary tumor of the brain composed of 
neoplastic glial cells in association with spindle 
cell sarcomatous elements (biphasic tissue 
patterns). (1-9) World Health Organization 
characterizes primary gliosarcoma as a grade 4 
neoplasm and a variant of glioblastoma 
multiform (10, 11) and gliosarcomashave an 
incidence of 1.8%-2.8% of that of 
glioblastomas. (5, 12, 13) 
 
Case report 
A 50-year female presented with fever of 20 
days duration, right sided headache and right 
hypochondrial pain of similar duration. She 
lapsed into altered sensorium three hours 
before presenting to emergency room and had 
two episodes of vomiting. She lapsed into 
altered sensorium after vomiting. Her general 
and systemic examination was unremarkable.  
Neurologically Glasgow coma scale (GCS) was 
E1V1M4, pupils were bilateral equal and 
reacting.  She was moving all four limbs 
equally to deep painful stimuli. Pulse rate was 
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56 per minute regular. The patient was 
intubated in emergency and ventilated. 
Computerized scan (CT) of brain revealed a 
well-circumscribed heterogeneous iso- to 
hyperdense lesion in the right temporal lobe 
with significant peri-lesional edema, mass 
effect and midline shift (Figure 1). Total 
leucocytes count was 26,500 per mm3 (N-86, 
L-09, E-01, 04. ESR was 36 mm in 1st hour. She 
was started on anti-edema measures. She 
underwent emergency right temporal 
craniotomy and total excision of the lass. The 
mass was avascular and firm to hard in 
consistency (Figure 2). Based on clinical 
features and intra-operative findings a 
diagnosis of tuberculoma was suspected.  
 
 
Figure 1 - CT scan brain plain showing a 
heterogeneously lesion in the right temporal lobe 
with significant peri-lesional edema, mass effect and 
midline shift 
 
Figure 2 - Intra-operative image showing (A) well 
defined mass lesion in right temporal lobe, (B) total 
excision of the mass (see inset) 
 
 
Figure 3 - Following up CT showing complete 
removal of the mass lesion 
 
 
Figure 4 - (A) Spindle shaped tumor cells with one 
foci showing necrosis and pseudopalisading pattern 
(H&E,X100), (B) Tumor with spindle shaped tumor 
cells, multinucleated tumor giant cells and congested 
blood vessels (H&E, X100), (C) Tumor with spindle 
shaped tumor cells and multinucleated tumor giant 
cells  (H&E, X100), (D) Spindle shaped tumor cells  
(H&E,X100), (E) Tumor cells with vacuolated 
cytoplasm (H&E, X100) and (F) Spindle shaped 
tumor cells with vesicular nuclei, prominent nucleoli 
and an atypical mitotic figure (H&E, X400) 
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Figure 5 - (A) Spindle shaped tumor cells positive for 
GFAP (GFAP, X100) and (B) Spindle shaped tumor 
cells positive for GFAP (GFAP, X400) 
 
In addition to broad spectrum antibiotics 
she was stated on ATT. Postoperative CT 
showed total excision of the tumor and 
reduction in cerebral edema, mass effect and 
midline shift (Figure 3). Multiple section 
studies showed lesion composed of spindle 
shaped cells arranged in fascicles. In some foci 
they are arranged irregularly. The tumor cells 
are having oval elongated vesicular nuclei with 
prominent nucleoli and eosinophilic 
cytoplasm. In some foci tumor cells show 
vacuolated cytoplasm. Few foci show tumor 
cells having eccentrically placed nuclei with 
abundant eosinophillic cytoplasm. Mono-
nucleated and multinucleated tumor giant 
cells are seen. Numerous atypical mitotic 
figures are noted. Occasional foci show 
necrosis and pseudo-pallisading pattern of 
arrangement of tumor cells. Glial component 
was seen in some foci (Figures 4 and 5). The 
patient received radiotherapy and 
chemotherapy. She is doing well at follow up. 
Discussion 
Gliosarcomas are usually located in the 
cerebral cortex (the temporal, frontal, parietal, 
and occipital lobes in decreasing frequency), 
most common in adults males in the fourth to 
sixth decades of life. (3, 5, 8, 12-16) Clinically 
these patients present with features of raised 
intracranial pressure due to an expanding 
space occupying lesion (i.e. headache, 
hemiparesis, seizures, and cognitive decline). 
(15, 17) The pathogenesis of gliosarcoma has 
been a topic of controversy and various 
theories have been proposed (1) the 
sarcomatous component originates from 
neoplastic transformation of hyperplastic 
blood vessels found in high-grade glioma, and 
(2) the recent theory suggests monoclonal 
origin of sarcomatous component originating 
via aberrant mesenchymal differentiation of 
the malignant glioma. (15, 18-20) 
Histologically, the gliosarcoma is composed of 
2 distinct malignant cell populations (biphasic 
tissue pattern), one component being 
gliomatous (heterogeneous infiltrative areas 
with hemorrhage and necrosis and stains for 
GFAP compatible with glioblastoma) and the 
other with malignant mesenchymal 
differentiation (a firm discrete mass 
compatible with sarcoma). Wrinkler, 2000 
#179} (3, 19-23) The presence of identical 
genetic alterations in both gliomatous and 
sarcomatous components strongly supports 
monoclonal origin of gliosarcomas, however 
the absence of amplification/over expression 
of the EGFR gene, a genetic hallmark of 
primary glioblastomas. 24 Appearance of 
gliosarcoma on CT is extremely variable and 
these lesions generally appear as a well-defined 
hyperdense mass with heterogeneous or ring 
enhancement due to a fibrous component with 
intense peritumoral edema and necrotic areas. 
(13, 15, 25-28) On magnetic resonance 
imaging (MRI) gliosarcoma appear as a 
heterogeneous mass both in T1- and T2-
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weighted images with irregular contrast 
enhancement with marked peritumoral edema 
(15, 25, 26) Management of gliosarcoma 
includes maximum surgical decompression 
with post-operative radiotherapy. (7, 9, 15, 29) 
The possible role of chemotherapy in GS is still 
undefined and could be explored in future 
studies. (7, 8, 13, 15, 20, 30) Metastases has 
been reported in up to one third of cases, 
mainly to the lungs, pleura, lymph nodes, bone 
marrow, liver, spinal cord, kidney and 
peripancreatic areas. (15, 17, 25) In spite of 
being recognized as two different pathologies 
studies have not shown any significant 
differences between gliosarcoma and 
glioblastoma with regard to age, sex, size, 
clinical presentation, and median survival. (3, 
7, 8, 14-16, 19, 20, 31) The predominance of 
the sarcomatous component has been shown 
to be associated with a better prognosis and a 
greater recurrence-free interval. (19) 
In summary, gliosarcoma is an aggressive 
tumor with a propensity to recur and re-grow 
with poor outcome. Future studies are needed 
to understand the true pathology of these 
biphasic tumors. 
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